Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By Joseph Haas
  
Dermatology
Incyte hopes to compete with biologics in hidradenitis suppurativa • Source: Shutterstock

More from Strategy

More from Therapy Areas